Literature DB >> 11577922

Recognition and management of scleroderma in children.

I Foeldvari1, N Wulffraat.   

Abstract

Juvenile scleroderma is a rare disease of childhood. The 2 main forms are localised and systemic scleroderma, although the pathogenesis of both forms is still unclear. The main clinical characteristic is the presence of skin sclerosis. Localised scleroderma can be divided into 3 different subtypes: morphoea, linear scleroderma and 'coup de sabre' lesions. The incidence is 0.2 to 0.4 per 100,000. 25 to 40% of patients are rheumatoid factor positive and 23 to 67% antinuclear antibody positive. An increased number of eosinophils occur in 31% of patients. Systemic sclerosis is an even rarer disease; approximately 10% of patients evolve the disease before the age of 18 years. The clinical presentation and disease course differ from the adult disease. This is reflected in the much better outcome. With regard to therapeutic options, there is still no gold standard for either form of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577922     DOI: 10.2165/00128072-200103080-00002

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  57 in total

1.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

2.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis.

Authors:  C M Artlett; J B Smith; S A Jimenez
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

3.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

4.  An epidemiological study of scleroderma in the West Midlands.

Authors:  A Silman; S Jannini; D Symmons; P Bacon
Journal:  Br J Rheumatol       Date:  1988-08

5.  Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome.

Authors:  A Duchini; S L Sessoms
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

6.  Systemic sclerosis: using high-resolution CT to detect lung disease in children.

Authors:  J M Seely; L T Jones; C Wallace; D Sherry; E L Effmann
Journal:  AJR Am J Roentgenol       Date:  1998-03       Impact factor: 3.959

7.  Antinuclear antibodies in children with localized scleroderma.

Authors:  A M Rosenberg; Y Uziel; B R Krafchik; S A Hauta; P A Prokopchuk; E D Silverman; R M Laxer
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

8.  Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients.

Authors:  P J Clements; P A Lachenbruch; M Sterz; G Danovitch; R Hawkins; A Ippoliti; H E Paulus
Journal:  Arthritis Rheum       Date:  1993-01

9.  Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome.

Authors:  N J Lindsey; R A Dawson; F I Henderson; M Greaves; P Hughes
Journal:  Br J Rheumatol       Date:  1993-02

10.  Autoantibodies against calpastatin in sera from patients with systemic sclerosis.

Authors:  S Sato; M Hasegawa; T Nagaoka; Y Takamatsu; N Yazawa; H Ihn; K Kikuchi; K Takehara
Journal:  J Rheumatol       Date:  1998-11       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.